PANDEMIC PREPAREDNESS THROUGH INTRANASAL ADMINISTRATION OF BROADLY EFFECTIVE MONOCLONAL ANTIBODIES AGAINST ALL INFLUENZA STRAINS

Respiratory infectious diseases pose a significant threat to global health, spreading rapidly and hindering containment. The COVID-19 pandemic, with over 450 million cases in two years, highlighted the need for effective preventive measures beyond vaccines and antivirals, which have notable limitations. Leyden Labs is pioneering a groundbreaking platform to counter evolving viral threats with nasal sprays developed using the world's most broadly neutralizing anti-influenza antibody (name disclosed in the short proposal). Our technology features high-affinity binding antibodies targeting the virus to prevent immune escape, with intranasal delivery ensuring targeted protection at the infection site for enhanced efficacy and convenience. Our primary market is EU healthcare providers, working closely with EU health authorities for effective pandemic response. Success in the EU will pave the way for global expansion, including the US market. Our nasal sprays will be available by prescription and through government partnerships, with revenue from insurance coverage and government contracts. This innovative platform aims to significantly improve pandemic preparedness and global health security. EU funding is crucial for financial support and strategic collaborations with EU healthcare providers, positioning us as leaders in healthcare innovation. The 2024 EIC Accelerator challenge will support the development of broad-spectrum monoclonal antibody-based therapeutics, ensuring efficacy against resistant variants.